Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- VACCINES11(5) · 2023
- 피인용
- Web of Science 43Scopus 43
- FWCI (Scopus)
- 1.42
- JCR IF
- JCR 2022 7.8
- ISSN
- 2076-393X
저자
초록
Bacteriophages have emerged as versatile tools in the field of bioengineering, with enormous potential in tissue engineering, vaccine development, and immunotherapy. The genetic makeup of phages can be harnessed for the development of novel DNA vaccines and antigen display systems, as they can provide a highly organized and repetitive presentation of antigens to immune cells. Bacteriophages have opened new possibilities for the targeting of specific molecular determinants of cancer cells. Phages can be used as anticancer agents and carriers of imaging molecules and therapeutics. In this review, we explored the role of bacteriophages and bacteriophage engineering in targeted cancer therapy. The question of how the engineered bacteriophages can interact with the biological and immunological systems is emphasized to comprehend the underlying mechanism of phage use in cancer immunotherapy. The effectiveness of phage display technology in identifying high-affinity ligands for substrates, such as cancer cells and tumor-associated molecules, and the emerging field of phage engineering and its potential in the development of effective cancer treatments are discussed. We also highlight phage usage in clinical trials as well as the related patents. This review provides a new insight into engineered phage-based cancer vaccines.
키워드
bacteriophagescancer immunotherapycombination therapygene therapyimmunological responsenanocarrierphage displayFIBROBLAST-GROWTH-FACTORBACTERIOPHAGE-LAMBDA DISPLAYTARGETED DRUG-DELIVERYIN-VIVOM13 BACTERIOPHAGEIMMUNE-RESPONSESGENE DELIVERYTUMOR-GROWTHDNA VACCINECOGNITIVE FUNCTION
식별자
- Scopus EID
- 2-s2.0-85160302161
- WoS UID
- 000996589400001



로그인
연구물 목록으로